Literature DB >> 19959410

Integrase inhibitors: why do we need a new drug class for HIV therapy?

Jürgen K Rockstroh1.   

Abstract

The introduction of integrase inhibitors as a new drug class for treatment of HIV have added a very potent and extremely well tolerated new treatment option to the HIV-armentarium. Particularly in patients with previously developed drug resistance, the availability of new active drugs offers great hope. Moreover, the in general excellent safety profile offers numerous opportunities for all lines of therapy and special patient populations. Clearly more data is needed to further explore and define the future role of integrase inhibitors in HIV-care.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19959410      PMCID： PMC3516821          DOI： 10.1186/2047-783x-14-s3-1

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN： 0949-2321            Impact factor:   2.175


  12 in total

Review 1.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

2.  Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

3.  Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Havilland Campbell; Kim M Strohmaier; Hong Wan; Robert M Danovich; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

4.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Authors:  Y Yazdanpanah; C Fagard; D Descamps; A M Taburet; C Colin; B Roquebert; C Katlama; G Pialoux; C Jacomet; C Piketty; D Bollens; J M Molina; G Chêne
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

5.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

6.  Rapidly ageing HIV epidemic among men who have sex with men in Australia.

Authors:  John M Murray; Ann M McDonald; Matthew G Law
Journal:  Sex Health       Date:  2009-03       Impact factor: 2.706

Review 7.  Raltegravir in treatment naive patients.

Authors:  F Cossarini; A Castagna; Adriano Lazzarin
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

Review 8.  Drug-drug interactions with raltegravir.

Authors:  David M Burger
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

Review 9.  The use of integrase inhibitors in treatment-experienced patients.

Authors:  Jose M Gatell
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

Review 10.  HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

Authors:  Martin Vogel; Mark Nelson
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175
View more
  2 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 2.  Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives.

Authors:  J B Senthil Kumar; Parthasarathi Das; Vibha Tandon
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.